$RPRX
Royalty Pharma plc Stock $rprx

$rprx Overview Financials Valuation SEC Filings Company Website

2020 Q4 Form 10-Q Financial Statement

#000180276820000010 Filed on November 12, 2020

Income Statement

Concept	2020 Q4	2020 Q3	2019 Q4
Revenue	$572.1M	$538.4M	$457.5M
YoY Change	25.05%	15.97%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$50.10M	$50.70M	$23.10M
YoY Change	116.88%	98.05%
% of Gross Profit
Research & Development	$7.800M	$5.096M	$15.90M
YoY Change	-50.94%	-77.55%
% of Gross Profit
Depreciation & Amortization	$5.800M	$5.800M	$5.800M
YoY Change	0.0%	0.0%
% of Gross Profit
Operating Expenses	$258.1M	$5.096M	-$874.4M
YoY Change	-129.52%	-77.55%
Operating Profit		$510.6M
YoY Change		-4.12%
Interest Expense	$56.40M	$31.44M	$114.5M
YoY Change	-50.74%	-54.29%
% of Operating Profit		6.16%
Other Income/Expense, Net	$1.600M	$113.7M	$100.0K
YoY Change	1500.0%	-222.94%
Pretax Income	$366.6M	$624.3M	$1.447B
YoY Change	-74.66%	41.87%
Income Tax	$0.00	$0.00	$0.00
% Of Pretax Income	0.0%	0.0%	0.0%
Net Earnings	$171.1M	$290.6M	$1.420B
YoY Change	-87.95%	-28.94%
Net Earnings / Revenue	29.91%	53.98%	310.47%
Basic Earnings Per Share		$0.79
Diluted Earnings Per Share	$429.3K	$0.79	$2.39
COMMON SHARES
Basic Shares Outstanding	388.1M shares	370.0M shares
Diluted Shares Outstanding		370.0M shares

Balance Sheet

Concept	2020 Q4	2020 Q3	2019 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$1.079B	$1.596B	$246.2M
YoY Change	338.13%
Cash & Equivalents	$1.009B	$1.553B	$246.2M
Short-Term Investments	$69.98M	$43.50M	$0.00
Other Short-Term Assets	$8.596M	$14.40M	$92.00K
YoY Change	9243.48%
Inventory
Prepaid Expenses
Receivables	$33.00M	$32.00M
Other Receivables	$6.000M	$5.000M
Total Short-Term Assets	$2.697B	$2.784B	$832.1M
YoY Change	224.12%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$454.9M	$439.8M	$124.1M
YoY Change	266.7%
Other Assets	$9.997M	$4.891M	$45.60M
YoY Change	-78.08%
Total Long-Term Assets	$13.32B	$13.21B	$11.62B
YoY Change	14.68%
TOTAL ASSETS
Total Short-Term Assets	$2.697B	$2.784B	$832.1M
Total Long-Term Assets	$13.32B	$13.21B	$11.62B
Total Assets	$16.02B	$15.99B	$12.45B
YoY Change	28.68%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$11.00M	$24.00M
YoY Change
Accrued Expenses	$152.0M	$110.0M
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due	$0.00	$0.00	$282.0M
YoY Change	-100.0%
Total Short-Term Liabilities	$307.9M	$270.0M	$333.4M
YoY Change	-7.66%
LONG-TERM LIABILITIES
Long-Term Debt	$5.817B	$5.812B	$5.956B
YoY Change	-2.34%
Other Long-Term Liabilities	$0.00	$110.0M	$0.00
YoY Change
Total Long-Term Liabilities	$5.817B	$5.922B	$5.956B
YoY Change	-2.34%
TOTAL LIABILITIES
Total Short-Term Liabilities	$307.9M	$270.0M	$333.4M
Total Long-Term Liabilities	$5.817B	$5.922B	$5.956B
Total Liabilities	$6.124B	$6.192B	$6.308B
YoY Change	-2.92%
SHAREHOLDERS EQUITY
Retained Earnings	$1.921B	$1.807B	$2.825B
YoY Change	-32.02%
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)	$2.317M	$2.155M	$4.266M
YoY Change	-45.69%
Treasury Stock Shares
Shareholders Equity	$4.819B	$4.452B
YoY Change
Total Liabilities & Shareholders Equity	$16.02B	$15.99B	$12.45B
YoY Change	28.68%

Cashflow Statement

Concept	2020 Q4	2020 Q3	2019 Q4
OPERATING ACTIVITIES
Net Income	$171.1M	$290.6M	$1.420B
YoY Change	-87.95%	-28.94%
Depreciation, Depletion And Amortization	$5.800M	$5.800M	$5.800M
YoY Change	0.0%	0.0%
Cash From Operating Activities	$565.6M	$508.9M	$897.4M
YoY Change	-36.97%	21.46%
INVESTING ACTIVITIES
Capital Expenditures	-$805.1M	-$802.5M	-$489.6M
YoY Change	64.44%	-3619.74%
Acquisitions
YoY Change
Other Investing Activities	-$27.30M	-$202.1M	-$151.1M
YoY Change	-81.93%	-65.89%
Cash From Investing Activities	-$832.4M	-$1.005B	-$640.6M
YoY Change	29.94%	63.27%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-277.4M	-357.4M	-566.5M
YoY Change	-51.03%	27.32%
NET CHANGE
Cash From Operating Activities	565.6M	508.9M	897.4M
Cash From Investing Activities	-832.4M	-1.005B	-640.6M
Cash From Financing Activities	-277.4M	-357.4M	-566.5M
Net Change In Cash	-544.2M	-853.1M	-309.7M
YoY Change	75.72%	78.85%
FREE CASH FLOW
Cash From Operating Activities	$565.6M	$508.9M	$897.4M
Capital Expenditures	-$805.1M	-$802.5M	-$489.6M
Free Cash Flow	$1.371B	$1.311B	$1.387B
YoY Change	-1.18%	230.99%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2019	us-gaap	Accounting Standards Update Extensible List AccountingStandardsUpdateExtensibleList	us-gaap:AccountingStandardsUpdate201613Member
	us-gaap	Accounting Standards Update Extensible List AccountingStandardsUpdateExtensibleList	us-gaap:AccountingStandardsUpdate201613Member
	us-gaap	Accounting Standards Update Extensible List AccountingStandardsUpdateExtensibleList	us-gaap:AccountingStandardsUpdate201613Member
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Entity Central Index Key EntityCentralIndexKey	0001802768
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2020
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Amendment Flag AmendmentFlag	false
	dei	Document Period End Date DocumentPeriodEndDate	2020-09-30
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-39329
	dei	Entity Registrant Name EntityRegistrantName	Royalty Pharma plc
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	X0
	dei	Local Phone Number LocalPhoneNumber	883-0200
	dei	City Area Code CityAreaCode	212
	dei	Entity Address Address Line1 EntityAddressAddressLine1	110 East 59th Street
	dei	Entity Address City Or Town EntityAddressCityOrTown	New York
	dei	Entity Address State Or Province EntityAddressStateOrProvince	NY
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	10022
	dei	Security12b Title Security12bTitle	Class A ordinary shares
	dei	Trading Symbol TradingSymbol	RPRX
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	false
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2020Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	388132400	shares
CY2020Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1552802000	USD
CY2019Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	246199000	USD
CY2020Q3	us-gaap	Trading Securities Debt TradingSecuritiesDebt	579527000	USD
CY2019Q4	us-gaap	Trading Securities Debt TradingSecuritiesDebt	94455000	USD
CY2020Q3	us-gaap	Notes And Loans Receivable Net Current NotesAndLoansReceivableNetCurrent	556856000	USD
CY2019Q4	us-gaap	Notes And Loans Receivable Net Current NotesAndLoansReceivableNetCurrent	452560000	USD
CY2020Q3	rprx	Accrued Royalty Receivable AccruedRoyaltyReceivable	32372000	USD
CY2019Q4	rprx	Accrued Royalty Receivable AccruedRoyaltyReceivable	33525000	USD
CY2020Q3	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	43507000	USD
CY2019Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	0	USD
CY2020Q3	rprx	Other Royalty Income Receivable Current OtherRoyaltyIncomeReceivableCurrent	4389000	USD
CY2019Q4	rprx	Other Royalty Income Receivable Current OtherRoyaltyIncomeReceivableCurrent	5241000	USD
CY2020Q3	us-gaap	Other Assets Current OtherAssetsCurrent	14398000	USD
CY2019Q4	us-gaap	Other Assets Current OtherAssetsCurrent	92000	USD
CY2020Q3	us-gaap	Assets Current AssetsCurrent	2783851000	USD
CY2019Q4	us-gaap	Assets Current AssetsCurrent	832072000	USD
CY2020Q3	us-gaap	Notes And Loans Receivable Net Noncurrent NotesAndLoansReceivableNetNoncurrent	11927576000	USD
CY2019Q4	us-gaap	Notes And Loans Receivable Net Noncurrent NotesAndLoansReceivableNetNoncurrent	10842052000	USD
CY2020Q3	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	34462000	USD
CY2019Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	51724000	USD
CY2020Q3	rprx	Equity Securities Fvni Noncurrent EquitySecuritiesFVNINoncurrent	637411000	USD
CY2019Q4	rprx	Equity Securities Fvni Noncurrent EquitySecuritiesFVNINoncurrent	380756000	USD
CY2020Q3	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	155019000	USD
CY2019Q4	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	131280000	USD
CY2020Q3	us-gaap	Derivative Assets Noncurrent DerivativeAssetsNoncurrent	7629000	USD
CY2019Q4	us-gaap	Derivative Assets Noncurrent DerivativeAssetsNoncurrent	42315000	USD
CY2020Q3	us-gaap	Equity Method Investments EquityMethodInvestments	439839000	USD
CY2019Q4	us-gaap	Equity Method Investments EquityMethodInvestments	124061000	USD
CY2020Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	4891000	USD
CY2019Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	45635000	USD
CY2020Q3	us-gaap	Assets Assets	15990678000	USD
CY2019Q4	us-gaap	Assets Assets	12449895000	USD
CY2020Q3	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	135595000	USD
CY2019Q4	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	31041000	USD
CY2020Q3	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	24388000	USD
CY2019Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	11177000	USD
CY2020Q3	rprx	Accrued Purchase Obligation Current AccruedPurchaseObligationCurrent	110000000	USD
CY2019Q4	rprx	Accrued Purchase Obligation Current AccruedPurchaseObligationCurrent	0	USD
CY2020Q3	us-gaap	Long Term Debt Current LongTermDebtCurrent	0	USD
CY2019Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	281984000	USD
CY2020Q3	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	0	USD
CY2019Q4	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	9215000	USD
CY2020Q3	us-gaap	Liabilities Current LiabilitiesCurrent	269983000	USD
CY2019Q4	us-gaap	Liabilities Current LiabilitiesCurrent	333417000	USD
CY2020Q3	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	5812047000	USD
CY2019Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	5956138000	USD
CY2020Q3	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	0	USD
CY2019Q4	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	18902000	USD
CY2020Q3	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	110000000	USD
CY2019Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	0	USD
CY2020Q3	us-gaap	Liabilities Liabilities	6192030000	USD
CY2019Q4	us-gaap	Liabilities Liabilities	6308457000	USD
CY2020Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2019Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2020Q3	rprx	Shareholders Contributions ShareholdersContributions	0	USD
CY2019Q4	rprx	Shareholders Contributions ShareholdersContributions	3282516000	USD
CY2020Q3	rprx	Deferred Shares Par Or Stated Value Per Share DeferredSharesParOrStatedValuePerShare	0.000001
CY2019Q4	rprx	Deferred Shares Par Or Stated Value Per Share DeferredSharesParOrStatedValuePerShare	0.000001
CY2020Q3	rprx	Deferred Shares Shares Outstanding DeferredSharesSharesOutstanding	298275000	shares
CY2020Q3	rprx	Deferred Shares Shares Issued DeferredSharesSharesIssued	298275000	shares
CY2019Q4	rprx	Deferred Shares Shares Issued DeferredSharesSharesIssued	0	shares
CY2019Q4	rprx	Deferred Shares Shares Outstanding DeferredSharesSharesOutstanding	0	shares
CY2020Q3	rprx	Deferred Shares Value Issued DeferredSharesValueIssued	0	USD
CY2019Q4	rprx	Deferred Shares Value Issued DeferredSharesValueIssued	0	USD
CY2020Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	2611976000	USD
CY2019Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	0	USD
CY2020Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	1807146000	USD
CY2019Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	2825212000	USD
CY2020Q3	us-gaap	Minority Interest MinorityInterest	5346835000	USD
CY2019Q4	us-gaap	Minority Interest MinorityInterest	35883000	USD
CY2020Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	34746000	USD
CY2019Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	2093000	USD
CY2020Q3	us-gaap	Treasury Stock Value TreasuryStockValue	2155000	USD
CY2019Q4	us-gaap	Treasury Stock Value TreasuryStockValue	4266000	USD
CY2020Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	9798648000	USD
CY2019Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	6141438000	USD
CY2020Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	15990678000	USD
CY2019Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	12449895000	USD
CY2020Q3	us-gaap	Revenues Revenues	538399000	USD
CY2019Q3	us-gaap	Revenues Revenues	464277000	USD
	us-gaap	Revenues Revenues	1550210000	USD
	us-gaap	Revenues Revenues	1356768000	USD
CY2020Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	5096000	USD
CY2019Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	22718000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	18510000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	67166000	USD
CY2020Q3	us-gaap	Provision For Loan And Lease Losses ProvisionForLoanAndLeaseLosses	-33792000	USD
CY2019Q3	us-gaap	Provision For Loan And Lease Losses ProvisionForLoanAndLeaseLosses	-122338000	USD
	us-gaap	Provision For Loan And Lease Losses ProvisionForLoanAndLeaseLosses	101498000	USD
	us-gaap	Provision For Loan And Lease Losses ProvisionForLoanAndLeaseLosses	-100161000	USD
CY2020Q3	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	5796000	USD
CY2019Q3	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	5796000	USD
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	17262000	USD
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	18128000	USD
CY2020Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	50732000	USD
CY2019Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	25603000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	131596000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	80378000	USD
CY2020Q3	us-gaap	Costs And Expenses CostsAndExpenses	27832000	USD
CY2019Q3	us-gaap	Costs And Expenses CostsAndExpenses	-68221000	USD
	us-gaap	Costs And Expenses CostsAndExpenses	268866000	USD
	us-gaap	Costs And Expenses CostsAndExpenses	65511000	USD
CY2020Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	510567000	USD
CY2019Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	532498000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	1281344000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	1291257000	USD
CY2020Q3	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	13743000	USD
CY2019Q3	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-8042000	USD
	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	33961000	USD
	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-21715000	USD
CY2020Q3	us-gaap	Interest Expense InterestExpense	31444000	USD
CY2019Q3	us-gaap	Interest Expense InterestExpense	68796000	USD
	us-gaap	Interest Expense InterestExpense	119217000	USD
	us-gaap	Interest Expense InterestExpense	205230000	USD
CY2020Q3	us-gaap	Gain Loss On Derivative Instruments Net Pretax GainLossOnDerivativeInstrumentsNetPretax	-7088000	USD
CY2019Q3	us-gaap	Gain Loss On Derivative Instruments Net Pretax GainLossOnDerivativeInstrumentsNetPretax	-13522000	USD
	us-gaap	Gain Loss On Derivative Instruments Net Pretax GainLossOnDerivativeInstrumentsNetPretax	-39886000	USD
	us-gaap	Gain Loss On Derivative Instruments Net Pretax GainLossOnDerivativeInstrumentsNetPretax	-78776000	USD
CY2020Q3	us-gaap	Equity Securities Fv Ni Unrealized Gain Loss EquitySecuritiesFvNiUnrealizedGainLoss	160226000	USD
CY2019Q3	us-gaap	Equity Securities Fv Ni Unrealized Gain Loss EquitySecuritiesFvNiUnrealizedGainLoss	-6924000	USD
	us-gaap	Equity Securities Fv Ni Unrealized Gain Loss EquitySecuritiesFvNiUnrealizedGainLoss	200955000	USD
	us-gaap	Equity Securities Fv Ni Unrealized Gain Loss EquitySecuritiesFvNiUnrealizedGainLoss	10020000	USD
CY2020Q3	us-gaap	Investment Income Net InvestmentIncomeNet	1587000	USD
CY2019Q3	us-gaap	Investment Income Net InvestmentIncomeNet	4581000	USD
	us-gaap	Investment Income Net InvestmentIncomeNet	7169000	USD
	us-gaap	Investment Income Net InvestmentIncomeNet	19082000	USD
CY2020Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-23337000	USD
CY2019Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	232000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-29000000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	253000	USD
CY2020Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	113687000	USD
CY2019Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-92471000	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	53982000	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-276366000	USD
CY2020Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	624254000	USD
CY2019Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	440027000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	1335326000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	1014891000	USD
CY2020Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2019Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2020Q3	us-gaap	Profit Loss ProfitLoss	624254000	USD
CY2019Q3	us-gaap	Profit Loss ProfitLoss	440027000	USD
	us-gaap	Profit Loss ProfitLoss	1335326000	USD
	us-gaap	Profit Loss ProfitLoss	1014891000	USD
CY2020Q3	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	333622000	USD
CY2019Q3	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	31045000	USD
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	531380000	USD
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	86752000	USD
CY2020Q3	us-gaap	Net Income Loss NetIncomeLoss	290632000	USD
CY2019Q3	us-gaap	Net Income Loss NetIncomeLoss	408982000	USD
	us-gaap	Net Income Loss NetIncomeLoss	803946000	USD
	us-gaap	Net Income Loss NetIncomeLoss	928139000	USD
CY2020Q3	us-gaap	Other Comprehensive Income Loss Derivative Excluded Component Increase Decrease After Adjustments And Tax OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAfterAdjustmentsAndTax	0	USD
CY2019Q3	us-gaap	Other Comprehensive Income Loss Derivative Excluded Component Increase Decrease After Adjustments And Tax OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAfterAdjustmentsAndTax	1622000	USD
	us-gaap	Other Comprehensive Income Loss Derivative Excluded Component Increase Decrease After Adjustments And Tax OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAfterAdjustmentsAndTax	4066000	USD
	us-gaap	Other Comprehensive Income Loss Derivative Excluded Component Increase Decrease After Adjustments And Tax OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAfterAdjustmentsAndTax	4811000	USD
CY2020Q3	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	7571000	USD
CY2019Q3	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-2900000	USD
	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	67245000	USD
	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	39000	USD
CY2020Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	7571000	USD
CY2019Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-1278000	USD
	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	71311000	USD
	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	4850000	USD
CY2020Q3	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	298203000	USD
CY2019Q3	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	407704000	USD
	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	875257000	USD
	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	932989000	USD
CY2020Q3	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	3768000	USD
CY2019Q3	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	0	USD
	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	15064000	USD
	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	0	USD
CY2020Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	294435000	USD
CY2019Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	407704000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	860193000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	932989000	USD
CY2020Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.79
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.88
CY2020Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.79
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.88
CY2020Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	369999000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	367753000	shares
CY2020Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	370002000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	367756000	shares
CY2020Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	9394961000	USD
CY2020Q3	rprx	Noncontrolling Interest Increase From Contributions NoncontrollingInterestIncreaseFromContributions	2105000	USD
CY2020Q3	us-gaap	Minority Interest Decrease From Distributions To Noncontrolling Interest Holders MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders	175348000	USD
CY2020Q3	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	848000	USD
CY2020Q3	us-gaap	Stockholders Equity Other StockholdersEquityOther	0	USD
CY2020Q3	us-gaap	Dividends Cash DividendsCash	54885000	USD
CY2020Q3	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	858000	USD
CY2020Q3	us-gaap	Profit Loss ProfitLoss	624254000	USD
CY2020Q3	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	7571000	USD
CY2020Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	9798648000	USD
CY2019Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	4653214000	USD
CY2019Q3	us-gaap	Minority Interest Decrease From Distributions To Noncontrolling Interest Holders MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders	196739000	USD
CY2019Q3	us-gaap	Profit Loss ProfitLoss	440027000	USD
CY2019Q3	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-2900000	USD
CY2019Q3	us-gaap	Other Comprehensive Income Loss Derivative Excluded Component Increase Decrease After Adjustments And Tax OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAfterAdjustmentsAndTax	1622000	USD
CY2019Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	4895224000	USD
CY2019Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	6141438000	USD
	rprx	Noncontrolling Interest Increase From Contributions NoncontrollingInterestIncreaseFromContributions	1450070000	USD
	rprx	Noncontrolling Interest Transfers Of Interests NoncontrollingInterestTransfersOfInterests	0	USD
	us-gaap	Minority Interest Decrease From Distributions To Noncontrolling Interest Holders MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders	865032000	USD
	rprx	Stock Issued During Period Value Issued For Registration StockIssuedDuringPeriodValueIssuedForRegistration	63000	USD
	us-gaap	Profit Loss ProfitLoss	624885000	USD
	rprx	Stock Issued During Period Value Issued To Partnerships StockIssuedDuringPeriodValueIssuedToPartnerships	1000	USD
	rprx	Stockholders Equity Value Effect Of Exchange And Reallocation StockholdersEquityValueEffectOfExchangeAndReallocation	-1000	USD
	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	1908474000	USD
	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	4588000	USD
	us-gaap	Stockholders Equity Other StockholdersEquityOther	0	USD
	us-gaap	Dividends Cash DividendsCash	54885000	USD
	us-gaap	Profit Loss ProfitLoss	710441000	USD
	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	67245000	USD
	us-gaap	Other Comprehensive Income Loss Derivative Excluded Component Increase Decrease After Adjustments And Tax OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAfterAdjustmentsAndTax	4066000	USD
CY2020Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	9798648000	USD
CY2018Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	4552079000	USD
	us-gaap	Minority Interest Decrease From Distributions To Noncontrolling Interest Holders MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders	672368000	USD
	us-gaap	Profit Loss ProfitLoss	1014891000	USD
	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	39000	USD
	us-gaap	Other Comprehensive Income Loss Derivative Excluded Component Increase Decrease After Adjustments And Tax OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAfterAdjustmentsAndTax	4811000	USD
	us-gaap	Treasury Stock Value Acquired Cost Method TreasuryStockValueAcquiredCostMethod	4228000	USD
CY2019Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	4895224000	USD
	rprx	Proceeds From Cash Collections From Royalties Received On Financing Receivables ProceedsFromCashCollectionsFromRoyaltiesReceivedOnFinancingReceivables	1549211000	USD
	rprx	Proceeds From Cash Collections From Royalties Received On Financing Receivables ProceedsFromCashCollectionsFromRoyaltiesReceivedOnFinancingReceivables	1402054000	USD
	rprx	Proceeds From Cash Collections From Royalties Received On Intangible Assets ProceedsFromCashCollectionsFromRoyaltiesReceivedOnIntangibleAssets	104131000	USD
	rprx	Proceeds From Cash Collections From Royalties Received On Intangible Assets ProceedsFromCashCollectionsFromRoyaltiesReceivedOnIntangibleAssets	107695000	USD
	rprx	Proceeds From Cash Collections From Other Royalties Received On Financing Receivables ProceedsFromCashCollectionsFromOtherRoyaltiesReceivedOnFinancingReceivables	12614000	USD
	rprx	Proceeds From Cash Collections From Other Royalties Received On Financing Receivables ProceedsFromCashCollectionsFromOtherRoyaltiesReceivedOnFinancingReceivables	24636000	USD
	us-gaap	Proceeds From Interest Received ProceedsFromInterestReceived	7476000	USD
	us-gaap	Proceeds From Interest Received ProceedsFromInterestReceived	18262000	USD
	rprx	Proceeds From Collateral Received On Derivative Instruments ProceedsFromCollateralReceivedOnDerivativeInstruments	45252000	USD
	rprx	Proceeds From Collateral Received On Derivative Instruments ProceedsFromCollateralReceivedOnDerivativeInstruments	360000	USD
	rprx	Payments For Collateral Posted On Derivative Instruments PaymentsForCollateralPostedOnDerivativeInstruments	0	USD
	rprx	Payments For Collateral Posted On Derivative Instruments PaymentsForCollateralPostedOnDerivativeInstruments	45630000	USD
	rprx	Payments To Terminate Derivative Instruments PaymentsToTerminateDerivativeInstruments	35448000	USD
	rprx	Payments To Terminate Derivative Instruments PaymentsToTerminateDerivativeInstruments	0	USD
	us-gaap	Equity Method Investment Dividends Or Distributions EquityMethodInvestmentDividendsOrDistributions	36041000	USD
	us-gaap	Equity Method Investment Dividends Or Distributions EquityMethodInvestmentDividendsOrDistributions	14059000	USD
	rprx	Payments For Ongoing Development Stage Funding PaymentsForOngoingDevelopmentStageFunding	18510000	USD
	rprx	Payments For Ongoing Development Stage Funding PaymentsForOngoingDevelopmentStageFunding	67166000	USD
	rprx	Payments For Operating Costs And Professional Services PaymentsForOperatingCostsAndProfessionalServices	129382000	USD
	rprx	Payments For Operating Costs And Professional Services PaymentsForOperatingCostsAndProfessionalServices	70125000	USD
	us-gaap	Interest Paid Net InterestPaidNet	102429000	USD
	us-gaap	Interest Paid Net InterestPaidNet	195335000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	1468956000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	1188810000	USD
	us-gaap	Proceeds From Equity Method Investment Dividends Or Distributions Return Of Capital ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital	15084000	USD
	us-gaap	Proceeds From Equity Method Investment Dividends Or Distributions Return Of Capital ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital	0	USD
	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	0	USD
	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	125121000	USD
	rprx	Payments To Acquire Equity Securities Fnni PaymentsToAcquireEquitySecuritiesFNNI	50000000	USD
	rprx	Payments To Acquire Equity Securities Fnni PaymentsToAcquireEquitySecuritiesFNNI	0	USD
	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	0	USD
	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	150000000	USD
	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	1095259000	USD
	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	750014000	USD
	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	609604000	USD
	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	161535000	USD
	us-gaap	Payments To Acquire Equity Method Investments PaymentsToAcquireEquityMethodInvestments	29262000	USD
	us-gaap	Payments To Acquire Equity Method Investments PaymentsToAcquireEquityMethodInvestments	22685000	USD
	us-gaap	Payments To Acquire Finance Receivables PaymentsToAcquireFinanceReceivables	1377085000	USD
	us-gaap	Payments To Acquire Finance Receivables PaymentsToAcquireFinanceReceivables	1254523000	USD
	rprx	Payments For Milestones PaymentsForMilestones	0	USD
	rprx	Payments For Milestones PaymentsForMilestones	250000000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-1926918000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-2090808000	USD
	rprx	Payments For Distributions To Shareholders And Unitholders PaymentsForDistributionsToShareholdersAndUnitholders	285353000	USD
	rprx	Payments For Distributions To Shareholders And Unitholders PaymentsForDistributionsToShareholdersAndUnitholders	564038000	USD
	us-gaap	Payments To Minority Shareholders PaymentsToMinorityShareholders	400893000	USD
	us-gaap	Payments To Minority Shareholders PaymentsToMinorityShareholders	117057000	USD
	rprx	Payments To Noncontrolling Interests Other PaymentsToNoncontrollingInterestsOther	74231000	USD
	rprx	Payments To Noncontrolling Interests Other PaymentsToNoncontrollingInterestsOther	0	USD
	rprx	Payment Of Dividends To Shareholders PaymentOfDividendsToShareholders	54885000	USD
	rprx	Payment Of Dividends To Shareholders PaymentOfDividendsToShareholders	0	USD
	rprx	Proceeds From Noncontrolling Interests Research And Development ProceedsFromNoncontrollingInterestsResearchAndDevelopment	6221000	USD
	rprx	Proceeds From Noncontrolling Interests Research And Development ProceedsFromNoncontrollingInterestsResearchAndDevelopment	0	USD
	rprx	Proceeds From Noncontrolling Interests Other ProceedsFromNoncontrollingInterestsOther	29985000	USD
	rprx	Proceeds From Noncontrolling Interests Other ProceedsFromNoncontrollingInterestsOther	0	USD
	rprx	Repayments Of Long Term Debt Scheduled Payments RepaymentsOfLongTermDebtScheduledPayments	94200000	USD
	rprx	Repayments Of Long Term Debt Scheduled Payments RepaymentsOfLongTermDebtScheduledPayments	220500000	USD
	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	11116196000	USD
	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	0	USD
	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	11891030000	USD
	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	0	USD
	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	46564000	USD
	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	0	USD
	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	0	USD
	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	4228000	USD
	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	1909651000	USD
	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	0	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	1764565000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-905823000	USD
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	1306603000	USD
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-1807821000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	246199000	USD
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1924211000	USD
CY2020Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1552802000	USD
CY2019Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	116390000	USD
	us-gaap	Use Of Estimates UseOfEstimates	The preparation of unaudited condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the unaudited condensed consolidated financial statements and accompanying notes. The current outbreak of the novel coronavirus, or COVID-19, could materially and adversely affect our results of operations, financial condition and cash flows. The full extent of the impact due to the COVID-19 pandemic will depend on future developments that are highly uncertain, including as a result of new information that may emerge concerning COVID-19 and the actions taken to contain it or treat COVID-19, as well as the economic impact. Given the uncertainty around the extent and timing of the potential future spread or mitigation efforts related to the current outbreak of COVID-19, the financial impact cannot be reasonably estimated at this time. Actual results may differ from those estimates. The results for the interim periods are not necessarily indicative of results for the full year.
CY2019Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	45600000	USD
CY2020Q2	rprx	Number Of Noncontrolling Interests Created NumberOfNoncontrollingInterestsCreated	2	partnership
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	Financial instruments that subject us to significant concentrations of credit risk consist primarily of cash and cash equivalents, marketable securities, financial royalty assets, receivables and derivatives. Our cash management and investment policy limits investment instruments to investment-grade securities with the objective to preserve capital and to maintain liquidity until the funds are needed for operations. Our cash and cash equivalents, and marketable securities balances at September 30, 2020 and December 31, 2019 were held with State Street Bank and Trust, Deutsche Bank, and Bank of America. Our primary operating accounts significantly exceed the FDIC limits.The majority of our royalty assets and receivables arise from contractual royalty agreements that entitle the Company to royalties on the sales of underlying biopharmaceutical products in the United States, Europe and the rest of the world, with concentrations of credit risk limited due to the broad range of marketers responsible for paying royalties to us and the variety of geographies from which our royalties on product sales are derived. The marketers paying us royalties on these products do not always provide, and are not necessarily required to provide, the breakdown of product sales by geography.
	rprx	Payments To Terminate Derivative Instruments PaymentsToTerminateDerivativeInstruments	35400000	USD
	rprx	Proceeds From Collateral Received On Derivative Instruments ProceedsFromCollateralReceivedOnDerivativeInstruments	45300000	USD
CY2020Q3	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	125121000	USD
CY2020Q3	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	73405000	USD
CY2020Q3	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	198526000	USD
CY2019Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	125121000	USD
CY2019Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	6159000	USD
CY2019Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	131280000	USD
CY2020Q3	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	43500000	USD
CY2020Q3	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	155000000.0	USD
CY2020Q3	us-gaap	Notes Receivable Gross NotesReceivableGross	13644089000	USD
CY2020Q3	rprx	Financing Receivable Allowance For Credit Loss Changes In Expected Cash Flows FinancingReceivableAllowanceForCreditLossChangesInExpectedCashFlows	828205000	USD
CY2020Q3	rprx	Financing Receivables After Allowance For Credit Loss Changes In Expected Cash Flows FinancingReceivablesAfterAllowanceForCreditLossChangesInExpectedCashFlows	12815884000	USD
CY2020Q3	rprx	Financing Receivable Allowance For Credit Loss Cumulative Adjustment And Credit Loss Expense Reversal FinancingReceivableAllowanceForCreditLossCumulativeAdjustmentAndCreditLossExpenseReversal	331452000	USD
CY2020Q3	us-gaap	Notes Receivable Net NotesReceivableNet	12484432000	USD
CY2019Q4	us-gaap	Notes Receivable Gross NotesReceivableGross	12163030000	USD
CY2019Q4	us-gaap	Financing Receivable Allowance For Credit Losses FinancingReceivableAllowanceForCreditLosses	868418000	USD
CY2019Q4	us-gaap	Notes Receivable Net NotesReceivableNet	11294612000	USD
CY2019Q4	us-gaap	Financing Receivable Allowance For Credit Losses FinancingReceivableAllowanceForCreditLosses	868418000	USD
	us-gaap	Financing Receivable Allowance For Credit Losses Recovery FinancingReceivableAllowanceForCreditLossesRecovery	457009000	USD
	us-gaap	Financing Receivable Allowance For Credit Losses Write Offs FinancingReceivableAllowanceForCreditLossesWriteOffs	494258000	USD
	us-gaap	Financing Receivable Change In Present Value Expense Reversal FinancingReceivableChangeInPresentValueExpenseReversal	2964000	USD
	us-gaap	Provision For Loan Losses Expensed ProvisionForLoanLossesExpensed	138747000	USD
CY2020Q3	us-gaap	Financing Receivable Allowance For Credit Losses FinancingReceivableAllowanceForCreditLosses	1159657000	USD
CY2020Q3	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	606216000	USD
CY2020Q3	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	571754000	USD
CY2020Q3	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	34462000	USD
CY2019Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	606216000	USD
CY2019Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	554492000	USD
CY2019Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	51724000	USD
CY2019Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	22700000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	67200000	USD
CY2020Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1000000.0	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	4700000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	0	USD
CY2020Q3	us-gaap	Profit Loss ProfitLoss	624254000	USD
	us-gaap	Profit Loss ProfitLoss	1335326000	USD
CY2020Q3	rprx	Net Income Loss Attributable To Parent Prior To Offering NetIncomeLossAttributableToParentPriorToOffering	0	USD
	rprx	Net Income Loss Attributable To Parent Prior To Offering NetIncomeLossAttributableToParentPriorToOffering	479842000	USD
CY2020Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	290632000	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	324104000	USD
CY2020Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	369999000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	367753000	shares
CY2020Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.79
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.88
CY2020Q3	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	290632000	USD
	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	324104000	USD
CY2020Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	369999000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	367753000	shares
CY2020Q3	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	3000	shares
	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	3000	shares
CY2020Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	370002000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	367756000	shares
CY2020Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.79
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.88
	us-gaap	Profit Loss ProfitLoss	1335326000	USD
	us-gaap	Profit Loss ProfitLoss	1014891000	USD
	us-gaap	Provision For Loan And Lease Losses ProvisionForLoanAndLeaseLosses	101498000	USD
	us-gaap	Provision For Loan And Lease Losses ProvisionForLoanAndLeaseLosses	-100161000	USD
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	17262000	USD
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	18128000	USD
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	6869000	USD
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	9129000	USD
	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	-39886000	USD
	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	-78776000	USD
	us-gaap	Equity Securities Fv Ni Unrealized Gain Loss EquitySecuritiesFvNiUnrealizedGainLoss	200955000	USD
	us-gaap	Equity Securities Fv Ni Unrealized Gain Loss EquitySecuritiesFvNiUnrealizedGainLoss	10020000	USD
	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	33961000	USD
	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-21715000	USD
	us-gaap	Equity Method Investment Dividends Or Distributions EquityMethodInvestmentDividendsOrDistributions	36041000	USD
	us-gaap	Equity Method Investment Dividends Or Distributions EquityMethodInvestmentDividendsOrDistributions	14059000	USD
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-30272000	USD
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	4588000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	0	USD
	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-8163000	USD
	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	370000	USD
	us-gaap	Increase Decrease In Finance Receivables IncreaseDecreaseInFinanceReceivables	1435536000	USD
	us-gaap	Increase Decrease In Finance Receivables IncreaseDecreaseInFinanceReceivables	1229245000	USD
	rprx	Increase Decrease In Cash Collections On Financing Receivables IncreaseDecreaseInCashCollectionsOnFinancingReceivables	1549211000	USD
	rprx	Increase Decrease In Cash Collections On Financing Receivables IncreaseDecreaseInCashCollectionsOnFinancingReceivables	1402054000	USD
	rprx	Increase Decrease In Debt Securities Available For Sale IncreaseDecreaseInDebtSecuritiesAvailableForSale	0	USD
	rprx	Increase Decrease In Debt Securities Available For Sale IncreaseDecreaseInDebtSecuritiesAvailableForSale	150000000	USD
	rprx	Increase Decrease In Accrued Royalty Receivable IncreaseDecreaseInAccruedRoyaltyReceivable	-1153000	USD
	rprx	Increase Decrease In Accrued Royalty Receivable IncreaseDecreaseInAccruedRoyaltyReceivable	-1884000	USD
	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	0	USD
	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	-150000000	USD
	rprx	Increase Decrease In Other Royalty Income Receivable IncreaseDecreaseInOtherRoyaltyIncomeReceivable	-852000	USD
	rprx	Increase Decrease In Other Royalty Income Receivable IncreaseDecreaseInOtherRoyaltyIncomeReceivable	-7573000	USD
	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	12935000	USD
	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	-4502000	USD
	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-44770000	USD
	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	45481000	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	11404000	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	1376000	USD
	us-gaap	Increase Decrease In Derivative Liabilities IncreaseDecreaseInDerivativeLiabilities	-34952000	USD
	us-gaap	Increase Decrease In Derivative Liabilities IncreaseDecreaseInDerivativeLiabilities	0	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	1468956000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	1188810000	USD
	us-gaap	Transfer Of Investments TransferOfInvestments	303679000	USD
	us-gaap	Transfer Of Investments TransferOfInvestments	0	USD
	rprx	Settlements With Equity Method Investments SettlementsWithEquityMethodInvestments	5700000	USD
	rprx	Settlements With Equity Method Investments SettlementsWithEquityMethodInvestments	0	USD
	rprx	Accrued Purchase Obligation Equity Investment AccruedPurchaseObligationEquityInvestment	220000000	USD
	rprx	Accrued Purchase Obligation Equity Investment AccruedPurchaseObligationEquityInvestment	0	USD
	rprx	Repayments Of Long Term Debt Contributions From Noncontrolling Interest Noncash RepaymentsOfLongTermDebtContributionsFromNoncontrollingInterestNoncash	1103774000	USD
	rprx	Repayments Of Long Term Debt Contributions From Noncontrolling Interest Noncash RepaymentsOfLongTermDebtContributionsFromNoncontrollingInterestNoncash	0	USD
	us-gaap	Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction	1177000	USD
	us-gaap	Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction	0	USD
	us-gaap	Other Comprehensive Income Loss Derivative Excluded Component Increase Decrease After Adjustments And Tax Parent OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAfterAdjustmentsAndTaxParent	4066000	USD
	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Reclassification Adjustments Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax	52181000	USD
	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Writedown Of Securities Net Of Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForWritedownOfSecuritiesNetOfTax	24022000	USD
	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax	428000	USD
CY2020Q3	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	135600000	USD
CY2019Q4	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	31000000.0	USD

Files In Submission

Name	View Source	Status
0001802768-20-000010-index-headers.html	Edgar Link	pending
0001802768-20-000010-index.html	Edgar Link	pending
0001802768-20-000010.txt	Edgar Link	pending
0001802768-20-000010-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
R9999.htm	Edgar Link	pending
report.css	Edgar Link	pending
rprx-20200920ex32.htm	Edgar Link	pending
rprx-20200930.htm	Edgar Link	pending
rprx-20200930.xsd	Edgar Link	pending
rprx-20200930ex311.htm	Edgar Link	pending
rprx-20200930ex312.htm	Edgar Link	pending
rprx-20200930_cal.xml	Edgar Link	unprocessable
rprx-20200930_def.xml	Edgar Link	unprocessable
rprx-20200930_htm.xml	Edgar Link	completed
rprx-20200930_lab.xml	Edgar Link	unprocessable
rprx-20200930_pre.xml	Edgar Link	unprocessable
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$RPRX
Royalty Pharma plc Stock $rprx

2020 Q4 Form 10-Q Financial Statement

#000180276820000010 Filed on November 12, 2020

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$RPRX Royalty Pharma plc Stock $rprx

2020 Q4 Form 10-Q Financial Statement

#000180276820000010 Filed on November 12, 2020

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$RPRX
Royalty Pharma plc Stock $rprx